Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Several label-supported statements are present (indications, IL-17A mechanism, general SC administration guidance). However, multiple dosing-related claims are inaccurate or not label-aligned (notably Psoriatic arthritis dose and the specific “400/600 mg” adjustment). Several monitoring/side-effect claims are generic and not substantiated by the provided label excerpts, and multiple potentially relevant label details (e.g., TB screening, vaccine guidance, infection/IBD precautions) are omitted.
Category Scores
Accurate Statements
Cosentyx (secukinumab) is a biologic medication used to treat autoimmune diseases including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Supported by Indications and Usage sections 1.1 (plaque psoriasis), 1.2 (psoriatic arthritis), and 1.3 (ankylosing spondylitis).
Cosentyx works by blocking the action of the protein interleukin-17A (IL-17A).
Supported by Mechanism of Action (12.1): selectively binds IL-17A and inhibits its interaction with the IL-17 receptor.
For plaque psoriasis, the recommended dosage of Cosentyx is 300 mg administered subcutaneously at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks.
Supported by Dosage and Administration 2.3 for adults with plaque psoriasis: 300 mg SC at Weeks 0,1,2,3,4 and every 4 weeks thereafter.
Patients should only adjust Cosentyx dosage under the guidance of a doctor.
Supported by Important Administration Instructions 2.2: COSENTYX is for use under the guidance and supervision of a healthcare provider.
If increasing the dosage, a doctor may increase Cosentyx to 400 mg or 600 mg every 4 weeks.
Not supported by provided label excerpts.
Unsupported Statements
Doctors may adjust Cosentyx dosage due to side effects.
The provided label excerpts do not state that dose adjustments are made for side effects.
Doctors may adjust Cosentyx dosage due to inadequate response to the typical dosage.
The provided label excerpts describe options such as considering dose increase (e.g., 150 mg to 300 mg every 4 weeks) for persistent active disease, but do not broadly support a general statement that dose adjustment is done for inadequate response in general terms across indications.
Doctors may adjust Cosentyx dosage due to interactions with other medications.
The provided Drug Interactions excerpt advises considering monitoring for therapeutic effect or concentration of the CYP450 substrate and consider dosage adjustment of the CYP450 substrate, not secukinumab dose.
If increasing the dosage, a doctor may increase Cosentyx to 400 mg or 600 mg every 4 weeks.
No provided label excerpt supports 400 mg or 600 mg dosing or that such increases are possible.
If decreasing the dosage, a doctor may decrease Cosentyx to 150 mg or 300 mg every 4 weeks.
The provided label excerpts do not generally support decreasing to 150 mg or 300 mg 'every 4 weeks' as a universal adjustment scheme; while 150 mg options exist for certain indications, the claim is framed as a dose-reduction option independent of indication/load and is not supported as stated.
A doctor may change Cosentyx administration schedule to every 2 weeks or every 6 weeks.
The provided label excerpt supports every 2 weeks only for inadequate response in hidradenitis suppurativa (300 mg every 2 weeks). It does not support an every-6-weeks schedule.
When adjusting Cosentyx dosage, the doctor will closely monitor the patient’s response to ensure it is effective and safe.
The provided label excerpts do not explicitly describe monitoring response as part of 'adjusting dosage' instructions.
When adjusting Cosentyx dosage, the patient will need regular check-ups to monitor response.
The provided label excerpts do not explicitly state a 'regular check-ups' requirement specifically tied to dosage adjustment.
Adjusting Cosentyx dosage may lead to new or worsening side effects such as injection site reactions, fatigue, or headaches.
The provided label excerpts for Adverse Reactions do not mention injection site reactions, fatigue, or headaches as consequences of dosage adjustment.
Adjusting the dosage of Cosentyx may be necessary in some cases to achieve optimal results.
The label excerpts include some specific dose consideration options (e.g., consider increasing to 300 mg every 4 weeks if active disease persists for PsA/AS), but do not support this broad 'necessary' statement.
Adjusting the dosage of Cosentyx is essential to determine with the doctor for individual needs.
Not directly supported by provided label language.
If not responding well to Cosentyx, a doctor may consider switching to a different medication.
The provided label excerpts do not discuss switching to alternative medications for lack of response.
The effects of adjusting Cosentyx dosage may take several weeks or months to become apparent.
The provided label excerpts do not describe a time-to-effect specifically for dose adjustment.
Contradictions
High
AI Statement
For psoriatic arthritis, the recommended dosage of Cosentyx is 300 mg administered subcutaneously at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks.
Label Reference
Dosage and Administration 2.4: Recommended PsA dosing is 150 mg (with or without loading) or consider increasing to 300 mg every 4 weeks if active PsA persists; it does not present 300 mg as the recommended PsA starting regimen in the provided excerpts.
Important Omissions
Pre-treatment evaluation guidance (TB screening; not recommended with active TB; initiate treatment of latent TB) and completion of age-appropriate vaccinations prior to initiation.
Importance:
Moderate
Warnings/precautions content relevant to safe use: infections risk, inflammatory bowel disease caution/monitoring, and avoidance of live vaccines.
Importance:
Moderate
Constrained and indication-specific dosing options (e.g., PsA and AS start at 150 mg with consideration of 300 mg every 4 weeks if active disease persists; hidradenitis suppurativa has an every-2-weeks consideration for inadequate response).
Importance:
High
Administration constraints: COSENTYX is for subcutaneous use only for certain formulations; intravenous use is for healthcare professional in a healthcare setting; pediatric self-administration restrictions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
At least one high-severity contradiction exists for psoriatic arthritis dosing (300 mg loading regimen stated instead of label-supported 150 mg with consideration of 300 mg if active disease persists). Several other dosing/schedule adjustment claims (400/600 mg; every-6-weeks; broad interaction-based dose changes) are unsupported and could lead to inaccurate dosing decisions if taken as label guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Incorrect psoriatic arthritis recommended dosing and unsupported/generalized dosing adjustment claims (400/600 mg; every-6-weeks; interaction-based secukinumab dose adjustments).
Suggested Improvement
Limit dosing statements to the label-supported regimens by indication and clarify that dose changes (e.g., to 300 mg every 4 weeks) are framed as considerations for persistent active disease in specific indications (PsA/AS). Remove or correct unsupported quantities/schedules (400/600 mg; every-6-weeks). For drug interactions, describe only the label-supported guidance (monitoring/adjustment of CYP450 substrate rather than secukinumab dose) and add key label safety screening (TB and vaccination/live vaccine avoidance) where relevant.